Novorapid Penfill (Insulin Aspart)

Insulin aspart, the active ingredient in Novorapid Penfill, is a rapid‑acting insulin analog presented as a solution for subcutaneous injection use. It lowers blood glucose in people with diabetes mellitus. GNH USA supplies Novorapid Penfill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Novorapid Penfill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Novorapid Penfill is a rapid‑acting insulin analog that controls post‑prandial glucose excursions in diabetes mellitus.

- Type 1 Diabetes Mellitus: Improves glycaemic control by replacing deficient basal insulin. - Type 2 Diabetes Mellitus: Provides mealtime‑focused faster insulin to supplement the patient own endogenous insulin. - Gestational Diabetes Mellitus: Helps to manage post‑meal blood glucose levels during pregnancy. - Hospital ​    

Common